Published in Pharm Res on August 01, 2015
Low Density Lipoprotein Receptor Related Proteins as Regulators of Neural Stem and Progenitor Cell Function. Stem Cells Int (2016) 0.77
Proteomics. Tissue-based map of the human proteome. Science (2015) 10.21
Isolation and primary culture of murine alveolar type II cells. Am J Respir Cell Mol Biol (1996) 3.77
LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev (2008) 3.46
Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. Nat Genet (2011) 3.03
Methodology for the measurement of mucociliary function in the mouse by scintigraphy. J Appl Physiol (1985) (2001) 2.10
Diverse roles for the LDL receptor family. Trends Endocrinol Metab (2002) 1.99
Distribution of the alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res (1992) 1.90
Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator. Proc Natl Acad Sci U S A (1992) 1.88
Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem (2005) 1.64
Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther (2014) 1.54
Isolation of highly pure alveolar epithelial type I and type II cells from rat lungs. Lab Invest (2004) 1.51
Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost (1989) 1.28
The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest (2010) 1.27
Tissue plasminogen activator. N Engl J Med (1988) 1.27
Fontan patient with plastic bronchitis treated successfully using aerosolized tissue plasminogen activator: a case report and review of the literature. Pediatr Cardiol (2008) 1.19
Prospective, longitudinal study of plastic bronchitis cast pathology and responsiveness to tissue plasminogen activator. Pediatr Cardiol (2011) 1.19
Treatment of plastic bronchitis in a Fontan patient with tissue plasminogen activator: a case report and review of the literature. Pediatrics (2002) 1.16
The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain. Am J Pathol (2009) 1.06
Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv (2010) 1.05
Mechanisms of alveolar protein clearance in the intact lung. Am J Physiol Lung Cell Mol Physiol (2004) 1.04
Management of plastic bronchitis with topical tissue-type plasminogen activator. Pediatrics (2012) 1.02
Alveolar epithelial transport in the adult lung. Respir Physiol Neurobiol (2007) 1.02
Stromal LRP1 in lung adenocarcinoma predicts clinical outcome. Clin Cancer Res (2011) 0.98
Immunophenotyping and protein profiling of Fontan-associated plastic bronchitis airway casts. Ann Am Thorac Soc (2013) 0.98
LRP1 assembles unique co-receptor systems to initiate cell signaling in response to tissue-type plasminogen activator and myelin-associated glycoprotein. J Biol Chem (2013) 0.97
The particle has landed--characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv (2010) 0.97
Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. Biochem Biophys Res Commun (2012) 0.94
Annexin A2 system in human biology: cell surface and beyond. Semin Thromb Hemost (2013) 0.92
Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung (1988) 0.91
Tissue plasminogen activator activates NF-κB through a pathway involving annexin A2/CD11b and integrin-linked kinase. J Am Soc Nephrol (2012) 0.91
Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs (1989) 0.90
Feasibility of tissue plasminogen activator formulated for pulmonary delivery. Pharm Res (2005) 0.90
Back to the future: inhaled drug products. J Pharm Sci (2013) 0.90
Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis. J Pharmacokinet Pharmacodyn (2009) 0.89
Human tissue-type plasminogen activator. Thromb Haemost (2014) 0.88
Accelerated dosing frequency of a pulmonary formulation of tissue plasminogen activator is well-tolerated in mice. Clin Exp Pharmacol Physiol (2008) 0.87
Fontan-associated protein-losing enteropathy and plastic bronchitis. J Pediatr (2015) 0.86
Safety of prolonged, repeated administration of a pulmonary formulation of tissue plasminogen activator in mice. Pulm Pharmacol Ther (2009) 0.86
Shedding of low-density lipoprotein receptor–related protein-1 in acute respiratory distress syndrome. Am J Respir Crit Care Med (2011) 0.85
Use of aerosolized tissue plasminogen activator in the treatment of plastic bronchitis. Ann Pharmacother (2013) 0.85
Pharmacotherapy challenges of Fontan-associated plastic bronchitis: a rare pediatric disease. Pharmacotherapy (2013) 0.84
Antagonists of the mannose receptor and the LDL receptor-related protein dramatically delay the clearance of tissue plasminogen activator. Circulation (1997) 0.84
TLR signaling prevents hyperoxia-induced lung injury by protecting the alveolar epithelium from oxidant-mediated death. J Immunol (2012) 0.83
Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species and isolated perfused rat liver. J Pharmacol Exp Ther (1990) 0.82
Plasmin overcomes resistance to prostaglandin E2 in fibrotic lung fibroblasts by reorganizing protein kinase A signaling. J Biol Chem (2011) 0.81
Involvement of the mannose receptor and p38 mitogen-activated protein kinase signaling pathway of the microdomain of the integral membrane protein after enteropathogenic Escherichia coli infection. Infect Immun (2012) 0.79
LRP and the receptor-mediated endocytosis of plasminogen activators. Ann N Y Acad Sci (1994) 0.78
Clearance receptors for tissue-type plasminogen activator. Int J Hematol (1994) 0.77
Receptor-mediated endocytosis of macromolecules and strategy to enhance their transport in alveolar epithelial cells. Expert Opin Drug Deliv (2014) 0.77
Airway fibrinogenolysis and the initiation of allergic inflammation. Ann Am Thorac Soc (2014) 0.77
Pediatric plastic bronchitis: case report and retrospective comparative analysis of epidemiology and pathology. Case Rep Pulmonol (2013) 0.76
Clofazimine Biocrystal Accumulation in Macrophages Upregulates Interleukin 1 Receptor Antagonist Production To Induce a Systemic Anti-Inflammatory State. Antimicrob Agents Chemother (2016) 0.78
Metabolomics as a Driver in Advancing Precision Medicine in Sepsis. Pharmacotherapy (2017) 0.75
Measurement of Short-Chain Fatty Acids in Respiratory Samples: Keep Your Assay above the Water Line. Am J Respir Crit Care Med (2020) 0.75